New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models.

New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models.
复制标题

DOI:
10.1038/s41375-019-0531-8
复制
发表时间:
2020-01
期刊:
影响因子:
11.4
通讯作者:
Durum SK
Durum SK
中科院分区:
医学1区
文献类型:
--
作者:
Hixon JA;Andrews C;Kashi L;Kohnhorst CL;Senkevitch E;Czarra K;Barata JT;Li W;Schneider JP;Walsh STR;Durum SK

文献摘要

参考文献

被引文献

相似文献

儿童T细胞急性淋巴细胞性白血病(T-ALL)细胞常含有白细胞介素7(IL-7)受体途径的突变,或对IL-7本身有反应。为了靶向T-ALL细胞上的IL-7受体,制备了抗人IL-7Rα链的小鼠单抗,并与人Ig G1恒定区嵌合。晶体结构表明,这两株单抗结合了不同的IL-7Rα表位。单抗介导的抗体依赖的细胞介导的细胞毒(ADCC)的患者来源的异种(PDX)T-ALL细胞,这是由两个单抗联合改善。在体内,单抗通过ADCC依赖和独立的机制对微小残留和既往疾病显示出治疗效果。化疗后复发的PDX T-ALL细胞显示IL-7Rα升高,单抗治疗对复发疾病有效,建议在复发T-ALL患者或化疗无效的患者中使用抗IL7Rα单抗。
Pediatric T cell acute lymphoblastic leukemia (T-ALL) cells frequently contain mutations in the interleukin-7 (IL-7) receptor pathway or respond to IL-7 itself. To target the IL-7 receptor on T-ALL cells, murine monoclonal antibodies (MAbs) were developed against the human IL-7Rα chain and chimerized with human IgG1 constant regions. Crystal structures demonstrate that the two MAbs bound different IL-7Rα epitopes. The MAbs mediated antibody-dependent cell-mediated cytotoxicity (ADCC) against patient-derived xenograft (PDX) T-ALL cells, which was improved by combining two MAbs. In vivo, the MAbs showed therapeutic efficacy via ADCC-dependent and independent mechanisms in minimal residual and established disease. PDX T-ALL cells that relapsed following a course of chemotherapy displayed elevated IL-7Rα, and MAb treatment is effective against relapsing disease, suggesting the use of anti-IL7Rα MAbs in relapsed T-ALL patients or patients that do not respond to chemotherapy.
DOI: 10.1016/j.ccr.2012.06.005
发表时间: 2012-08-14
期刊: Cancer cell
影响因子: 50.3
作者:
Roberts KG;Morin RD;Zhang J;Hirst M;Zhao Y;Su X;Chen SC;Payne-Turner D;Churchman ML;Harvey RC;Chen X;Kasap C;Yan C;Becksfort J;Finney RP;Teachey DT;Maude SL;Tse K;Moore R;Jones S;Mungall K;Birol I;Edmonson MN;Hu Y;Buetow KE;Chen IM;Carroll WL;Wei L;Ma J;Kleppe M;Levine RL;Garcia-Manero G;Larsen E;Shah NP;Devidas M;Reaman G;Smith M;Paugh SW;Evans WE;Grupp SA;Jeha S;Pui CH;Gerhard DS;Downing JR;Willman CL;Loh M;Hunger SP;Marra MA;Mullighan CG
通讯作者: Mullighan CG
DOI: 10.1182/blood-2016-03-679209
发表时间: 2016-07-28
期刊: BLOOD
影响因子: 20.3
作者:
Cramer, Sarah D.;Aplan, Peter D.;Durum, Scott K.
通讯作者: Durum, Scott K.
DOI: 10.3892/ijo.2018.4392
发表时间: 2018-07-01
影响因子: 5.2
作者:
Kim, Myoung Jun;Choi, Sung Kyung;You, Jueng Soo
通讯作者: You, Jueng Soo
DOI: 10.1182/blood.v96.1.297.013k24_297_306
发表时间: 2000-07-01
期刊: BLOOD
影响因子: 20.3
作者:
Karawajew, L;Ruppert, V;Ludwig, WD
通讯作者: Ludwig, WD
DOI: 10.1182/blood-2014-06-580480
发表时间: 2015-03-12
期刊: BLOOD
影响因子: 20.3
作者:
Maude, Shannon L.;Dolai, Sibasish;Teachey, David T.
通讯作者: Teachey, David T.